Long-Term Real-Life Experience With Rituximab in Adult Finnish Patients With Rheumatoid Arthritis Refractory or With Contraindication to Anti–Tumor Necrosis Factor Drugs

Miliary tuberculosis in a rheumatoid arthritis patient receiving long-term tumor necrosis factor monoclonal antibody therapy

Pulmonology ◽

10.1016/j.pulmoe.2021.01.010 ◽

2021 ◽

Author(s):

C.-R. Wang ◽

W.-C. Lin ◽

Y.-S. Tsai

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Rheumatoid Arthritis Patient ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Antibody Therapy ◽

Miliary Tuberculosis ◽

Monoclonal Antibody Therapy ◽

Long-term Survival of Subcutaneous Anti-tumor Necrosis Factor Biological Drugs Administered Between 2008 and 2012 in a Cohort of Rheumatoid Arthritis Patients

Reumatología Clínica (English Edition) ◽

10.1016/j.reumae.2018.09.001 ◽

2019 ◽

Vol 15 (1) ◽

pp. 54-57

Author(s):

Noelia Alvarez Rivas ◽

Tomas R. Vazquez Rodriguez ◽

Jose A. Miranda Filloy ◽

Carlos Garcia-Porrua ◽

Amalia Sanchez-Andrade Fernández

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Biological Drugs ◽

Term Survival ◽

Long Term Survival ◽

Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis

Advances in Therapy ◽

10.1007/s12325-018-0869-8 ◽

2019 ◽

Vol 36 (3) ◽

pp. 721-745

Author(s):

László Gulácsi ◽

Zsombor Zrubka ◽

Valentin Brodszky ◽

Fanni Rencz ◽

Rieke Alten ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Literature Review ◽

Systematic Literature Review ◽

Tumor Necrosis ◽

Meta Analysis ◽

Term Efficacy ◽

Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?

Arthritis & Rheumatism ◽

10.1002/art.10274 ◽

2002 ◽

Vol 46 (7) ◽

pp. 1971-1972 ◽

Cited By ~ 17

Author(s):

Philip G. Conaghan ◽

Mark A. Quinn ◽

Philip O'Connor ◽

Richard J. Wakefield ◽

Zunaid Karim ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

High Dose ◽

Very High ◽

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database

Rheumatology International ◽

10.1007/s00296-014-3045-8 ◽

2014 ◽

Vol 34 (12) ◽

pp. 1729-1736 ◽

Cited By ~ 8

Author(s):

Ryoko Sakai ◽

◽

Soo-Kyung Cho ◽

Toshihiro Nanki ◽

Ryuji Koike ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Serious Infection ◽

Necrosis Factor ◽

Over Time

Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry

Arthritis Care & Research ◽

10.1002/acr.22788 ◽

2016 ◽

Vol 68 (4) ◽

pp. 432-439 ◽

Cited By ~ 41

Author(s):

Ennio Giulio Favalli ◽

Francesca Pregnolato ◽

Martina Biggioggero ◽

Andrea Becciolini ◽

Alessandra Emiliana Penatti ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Retention Rate ◽

Real Life ◽

First Line ◽

Life Data ◽

Real Life Data ◽

Direct Comparative Effectiveness Among 3 Anti–Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis

JCR Journal of Clinical Rheumatology ◽

10.1097/rhu.0000000000000358 ◽

2016 ◽

Vol 22 (2) ◽

pp. 57-62 ◽

Cited By ~ 10

Author(s):

Pedro Santos-Moreno ◽

Guillermo Sánchez ◽

Danny Gómez ◽

Juan Bello-Gualtero ◽

Carlos Castro

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Comparative Effectiveness ◽

Tumor Necrosis ◽

Real Life ◽

FRI0214 Long-term efficacy and safety of sirukumab in patients with active rheumatoid arthritis despite anti-tumor necrosis factor therapy: results of the randomized, phase 3 sirround-t study

10.1136/annrheumdis-2017-eular.6486 ◽

2017 ◽

Author(s):

Y Tanaka ◽

D Aletaha ◽

P Agarwal ◽

R Kurrasch ◽

PP Tak ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Active Rheumatoid Arthritis ◽

Efficacy And Safety ◽

Phase 3 ◽

Term Efficacy ◽

Factor Therapy ◽

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Arthritis Research & Therapy ◽

10.1186/s13075-015-0583-8 ◽

2015 ◽

Vol 17 (1) ◽

Cited By ~ 33

Author(s):

Ryoko Sakai ◽

◽

Soo-Kyung Cho ◽

Toshihiro Nanki ◽

Kaori Watanabe ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Practice ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients

Joint Bone Spine ◽

10.1016/j.jbspin.2012.02.006 ◽

2012 ◽

Vol 79 (5) ◽

pp. 520-521

Author(s):

Sanae Ali Ou Alla ◽

Cedric Lukas ◽

Najia Hajjaj-Hassouni ◽

René Marc Flipo ◽

Bernard Combe ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Blocker Therapy ◽

Subcutaneous Tumor ◽

Tumor Necrosis Factor Blocker ◽

Das28 Remission ◽